购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

SB 202190

SB 202190
SB 202190 (FHPI) 是一种 p38 MAPK 抑制剂,可以抑制 p38α 和 p38β2 (IC50=50/100 nM),具有选择性和细胞渗透性。SB 202190 具有抗肿瘤活性,还可以诱导人胚胎干细胞向心肌细胞分化。
产品编号 T2301Cas号 152121-30-7
选择批次:
纯度:99.84%
联系我们获取更多批次信息

SB 202190

产品编号 T2301别名 FHPI, SB202190Cas号 152121-30-7
SB 202190 (FHPI) 是一种 p38 MAPK 抑制剂,可以抑制 p38α 和 p38β2 (IC50=50/100 nM),具有选择性和细胞渗透性。SB 202190 具有抗肿瘤活性,还可以诱导人胚胎干细胞向心肌细胞分化。
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
规格价格库存数量
10 mg¥ 467现货
25 mg¥ 839现货
50 mg¥ 997现货
100 mg¥ 1,675现货
200 mg¥ 2,683现货
1 mL x 10 mM (in DMSO)¥ 333现货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多

"SB 202190"的相关化合物库

产品介绍

生物活性
产品描述
SB 202190 (FHPI) is a p38 MAPK inhibitor that inhibits p38α and p38β2 (IC50=50/100 nM) selectively and cell-permeably. SB 202190 has antitumor activity and also induces the differentiation of human embryonic stem cells into cardiomyocytes.
靶点活性
p38β:100 nM (cell free), p38α:50 nM (cell free)
体外活性
方法:人 Tenon 成纤维细胞用 SB 202190 (5-50 μM) 处理,使用 MTT assay 检测细胞活力。
结果:SB 202190 对细胞有毒性,IC50 为 17.2 μM。[1]
方法:人脐静脉内皮细胞 HUVEC 用 SB 202190 (0.1-10 μM) 处理 6-48 h,使用 Western Blot 方法检测靶点蛋白表达水平。
结果:SB 202190 孵育 24 小时后,LC3A/B-I 转化为 PE 偶联的 LC3A/B-II 以浓度依赖的方式增加。[2]
体内活性
方法:为研究 p38 MAPK 在急性内毒素血症小鼠中的作用,将 SB 202190 (2 mg/kg) 腹腔注射给 C57BL/6 小鼠,30 min 后注射 LPS (10 mg/kg)。
结果:SB 202190 预处理可降低 TNF-α水平,显著逆转 LPS 诱导的左心室抑制,降低 LPS 诱导的死亡率。[3]
方法:为检测体内抗肿瘤活性,将 SB 202190 (5 mg/kg) 和 OSI-027 (10 mg/kg) 腹腔注射给携带人 CRC 肿瘤 SW620 的 BALB/c 小鼠,每天一次,持续十天。
结果:单独使用 SB 202190 增强了 SW620 异种移植物的肿瘤增殖和肿瘤负荷。SB 202190 和 OSI-027 的联合显著减弱了异种移植物肿瘤的生长。[4]
激酶实验
All protein kinase activities were linear with respect to time in every incubation. Assays were performed either manually for 10 min at 30 °C in 50 μl incubations using [γ-32P]ATP or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 min at ambient temperature in 25 μl incubations using [γ-32P]ATP. The concentrations of ATP and magnesium acetate were 0.1 mM and 10 mM respectively, unless stated otherwise. This concentration of ATP is 5–10-fold higher than the Km for ATP of most of the protein kinases studied in the present paper, but lower than the normal intracellular concentration, which is in the millimolar range. All assays were initiated with MgATP. Manual assays were terminated by spotting aliquots of each incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays were terminated by the addition of 5 μl of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers were then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity [1].
细胞实验
For transfection, A549 cells were seeded in 6-well plates to obtain 30% confluence at the time of transfection. Xtreme siRNA transfection reagent was used to transfect siRNA to a final concentration of 100 nM. Inhibition of gene expression by siRNA was determined after 48 hours by Western analysis. Cells were harvested, and the nuclear extract or total cell lysate was assayed for AP-1 DNA binding or Western blotting, respectively. HEK293T cells were cultured in complete DMEM. phCMV2-HA-MLK3 was transfected into HEK293T cells using genejammer transfection reagent using manufacturer's instructions. After 48 hours, cells were either untreated or treated with 5 or 10 μM SB202190 or SB203580 for 4 hours. Following treatment cell lysates were prepared using lysis buffer (50 mM Tris-HCl at pH 7.5, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 50 mM NaF, 10 mM sodium pyrophosphate, 25 mM β- glycerophosphate, 1 mM PMSF, 30 μL/mL aprotinin, and 1 mM Na3VO4). 500 μg of total protein was immunoprecipitated with anti-HA-agarose conjugate. Phospho-MLK3 (Thr277/Ser281) was detected in western blotting using phosphospecific antibodies. The expression vector was transfected into HEK293T cells using Genejammer as stated earlier. After 48 hours, cell lysates was prepared and Flag-MKK7 was immunoprecipitated using anti-Flag-agarose conjugate. The Flag-MKK7 was used as a substrate for MLK3 kinase assay [3].
动物实验
The pharmacological efficacy of SB-ULS-LZM was evaluated in the unilateral ischemia-reperfusion (I/R) rat model. At 2 h before the ischemia procedure, rats were injected with SB-ULS-LZM (32 mg/kg. conjugate, equivalent to 752 g/kg SB202190), vehicle (5% glucose), or free SB202190 (800 g/kg). SB-ULS-LZM was dissolved in 5% glucose, whereas SB202190 was dissolved in 20% hydroxypropyl-β-cyclodextrin solution with 5% dimethyl sulfoxide as described earlier. Compounds were administered i.v. via the penis vein as described above. Animals were allowed to recover and placed back into the cages until the induction of renal ischemia. Rats were operated, and the renal artery and vein were clamped under microscope to stop renal blood flow. After 45 min, clamps were removed, and reperfusion of the kidney was observed before closing of the wound. Sham-operated animals (n 3) received the same surgical procedure, with the exception of ischemia, and were included as a control group. After 4 days, animals were sacrificed, and blood samples were collected from the abdominal aorta. Kidneys were isolated after gently flushing the organs with saline and preserved in 4% formalin for preparation of paraffin-embedded sections or frozen in ice-cold isopentane for preparation of cryosections [2].
别名FHPI, SB202190
化学信息
分子量331.34
分子式C20H14FN3O
CAS No.152121-30-7
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 50 mg/mL (150.9 mM)
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM3.0180 mL15.0902 mL30.1805 mL150.9024 mL
5 mM0.6036 mL3.0180 mL6.0361 mL30.1805 mL
10 mM0.3018 mL1.5090 mL3.0180 mL15.0902 mL
20 mM0.1509 mL0.7545 mL1.5090 mL7.5451 mL
50 mM0.0604 mL0.3018 mL0.6036 mL3.0180 mL
100 mM0.0302 mL0.1509 mL0.3018 mL1.5090 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy SB 202190 | purchase SB 202190 | SB 202190 cost | order SB 202190 | SB 202190 chemical structure | SB 202190 in vivo | SB 202190 in vitro | SB 202190 formula | SB 202190 molecular weight